Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 study of ADX-629 in patients with Sjögren-Larsson Syndrome

Next Previous
Trial Profile

Phase 2 study of ADX-629 in patients with Sjögren-Larsson Syndrome

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADX-629 (Primary)
  • Indications Sjogren-Larsson syndrome
  • Focus Therapeutic Use
  • Sponsors Aldeyra Therapeutics

Most Recent Events

  • 20 Jun 2024 According to an Aldeyra Therapeutics media release, following positive biomarker results in adults ADX-629 advanced to the pediatric cohort of the Phase 2 clinical trial in Sjogren-Larsson Syndrome. Top-line results from approximately five pediatric patients are expected in 2025.
  • 04 Jan 2024 According to an Aldeyra Therapeutics media release, the company expects to submit an application to the FDA of a proposed expansion of the Phase 2 clinical trial of the investigational RASP modulator ADX-629 in Sjogren-Larsson Syndrome to include pediatric patients in first half of 2024.
  • 04 May 2023 According an Aldeyra Therapeutics media release, Top-line results are expected in the second half of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top